Please assess the completion status of the following clinical trial:

Trial Title: Deescalating Carbapenems in Hospital Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Hospitalization in conventional ward; (3) Receiving a curative treatment with a carbapenem for at least 24 hours and less than 3 days for a recent infection due to an ESBL-PE, either initially or secondary documented~* With a site of infection originating from the urinary, digestive or biliary tract~* Identification of an ESBL-PE for which susceptibility results (by the method of discs) have shown to be susceptible to more narrow spectrum beta-lactams (cephalosporins, b-lactamase inhibitors, monobactams)~* With sepsis signs and symptoms controlled after initiation of antibiotic therapy~* For a community-acquired or hospital-acquired infection.~Exclusion Criteria:~* Pregnancy or breastfeeding~* Neutropenia (PNN \< 500/mm3)~* Hospitalization in intensive care unit or bone marrow transplant unit~* Documented polymicrobial infection~* Culture of an ESBL-PE susceptible to an orally active drug (such as fluoroquinolones, cotrimoxazole) and possible use of one of these drugs~* Need to treat a EBLSE infection(s) wtih more than drug other than carbapenems~* Need to maintain an association with an aminoglycoside~* Colonization without signs and symptoms of sepsis~* Sepsis signs and symptoms not controlled at the time of enrolment~* Known allergy to beta-lactams~* Failure to complete medical examination~* Absence of signed written consent.~* Patient without healthcare insurance (French social security, CMU or AME)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Maintaining carbapenem therapy (Type: ACTIVE_COMPARATOR): Intravenous therapy, Maintaining carbapenem therapy
- Deescalation therapy (Type: ACTIVE_COMPARATOR): Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE. Deescalation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).